Literature DB >> 8274426

Mechanism of synergistic action of all-trans- or 9-cis-retinoic acid and interferons in breast cancer cells.

C Marth1, M Widschwendter, G Daxenbichler.   

Abstract

Combination of all-trans-retinoic acid (RA) with either interferon-alpha or -gamma resulted in a synergistic amplification of the anti-proliferative effect on cultured breast cancer cells. RA could be replaced by other biologically active retinoids. The synergism was also observed for the induction of 2'-5'-oligoadenylate synthetase, an enzyme which is involved in anti-viral activity of interferons and possibly in growth regulation of tumor cells. Combination of RA with interferon-gamma increased the down-regulation of specific binding sites for [125I]interferon-gamma. On the other hand interferons had no effect on the cytoplasmic binding protein for RA. Comparing all-trans- with 9-cis-RA, the latter was more effective in inhibiting tumor cell growth and in inducing synergism with interferon-gamma. This would indicate that retinoic X receptors are more important in mediating these effects than the RA receptors (RARs). This assumption is also supported by the failure of Ro-415253, a specific RAR-alpha antagonist, to reduce the synergistic interaction of RA with interferon with respect to growth inhibition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8274426     DOI: 10.1016/0960-0760(93)90065-5

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  2 in total

1.  Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients.

Authors:  F Formelli; E Cavadini; L Mascheroni; F Belli; N Cascinelli
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro.

Authors:  M Widschwendter; A Widschwendter; T Welte; G Daxenbichler; A G Zeimet; A Bergant; J Berger; J P Peyrat; S Michel; W Doppler; C Marth
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.